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SUMMARY
Objective: To identify HTLV-II prevalence in blood donors at the Blood Center Net of 
Ceará (Hemorrede do Ceará - HEMOCE)and epidemiological aspects of positive cases. 
Methods: Cases considered positive were surveyed from data bases through the immu-
noenzymatic method ELISA and confirmed by Western Blot from 2001 to 2008. In this 
period, 679,610 blood samples from voluntary donors were tested. Results: From all 
donors, 164 samples were actually positive in both tests; of these, 33 (20.1%) were typed 
as HTLV-II, showing a prevalence of 0.006%. In positive cases, a mean age 28.2 years, 
and a predominantly male gender (54.5%) were observed, the race was mixed in 78.8%, 
most donors had Fortaleza as hometown (72.7%), with 51.5% being married/consen-
sual union, and 33.3% reported to have completed high school education. Conclusion: 
Although HTLV-II infection is low, its presence is universal, being similar in males and 
females mostly in urban centers. The need of preventive measures as a way of avoiding 
infection spread is stressed.
Keywords: Anti-HTLV-II antibodies; HTLV-II infections; human T-lymphotropic virus 
II; blood donors; hemotherapy service.
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INTRODUCTION
Blood donation is one of the noblest gestures of the human 
being in the struggle for life. However, measures to prevent 
the transmission of diseases, among which the human T-
lymphotropic virus (HTLV) has its type 1 associated with 
the pathogenesis of the tropical spastic paraparesis/my-
elopathy associated with the human T-cell lymphotropic 
virus (TSP/HAM), is to be considered. However, HTLV-II 
has not been clearly associated with any disease yet1. Thus, 
the assessment for anti-HTLV-I/II antibodies in blood do-
nors by hematology centers became a requirement.
The transmission of HTLV infection via blood trans-
fusion was firstly described in 1984 in Japan2. The virus 
transmission may also occur through needle shared use, 
sexual contact and breastfeeding3,4. The first country to 
implant the antibody assessment for HTLV was Japan in 
November 1986, followed by the United States of America 
in January 1988, France in May 1989, Canada in 19905-7. 
In Brazil, the requirement of assessing for anti-HTLV-I/II 
antibodies in hemotherapy services was determined by the 
Ordinance no. 1376 of Ministry of Health from November 
19, 19938.
HTLV (human T-cell lymphotropic virus) viruses 
belong to the Retroviridae family, genus Deltaretrovirus. 
HTLV-I was described in 1980 as the first human retro-
virus9. HTLV-II was isolated in 1982 from a patient with 
hairy T-cell leukemia10.
HTLV infections can be found in several continents, 
but their distribution shows there are areas with higher 
endemicity, as well as peculiarities according to th HTLV 
type11. HTLV-II infection aects distinct and supposedly 
unrelated population groups, living in dierent geographi-
cal regions, such as North-American, Central-American 
and South-American natives, Central Africa Pygmies and 
Asian Mongol people, injectable drug users in the United 
States of America, in Europe and in Asian countries, such 
as Vietnam12.
In Brazil, the presence of HTLV-II was initially report-
ed in native communities in the Amazon region12,13 and 
later in Southern Brazilian natives14. More recently, the 
HTLV-2b presence has been detected in Brazilian Ama-
zonia15.
The objective of this study was to identify the HTLV-II 
prevalence in blood donors at Hemocentro do Estado do 
Ceará and assess its epidemiology.
METHODS
This is an epidemiological study with a data base survey of 
blood donor data of the blood center net in Ceará, Brazil, 
in cases considered HTLV-II-positive. The blood center 
net comprises the coordinator blood center in Fortaleza 
(HEMOCE) and regional blood centers located on the 
Northern (Sobral), Middle-Northern (Quixadá), Southern 
(Crato) and Middle-Southern (Iguatu) regions. The survey 
period was from 2001 to 2008, taking into account donors 
considered able following clinical screening. As an HTLV 
screening test, the immunoenzymatic assay (IEA) ELISA, 
which detects specific virus antibodies generated from the 
immunologic response was used.
The test was done in the sample collected at the blood 
donation according to the method specified by the manu-
facturer (Abbot-Murex). Reactive results indicated the 
presence of antibodies to HTLV-I/II; the negative result 
(“non-reactive serum”) shows an absence of the antibod-
ies. The test reading can be inconclusive.
Donors with definite reactive or inconclusive results by 
ELISA were invited to return for a new sample collection 
(second sample) and the test would be rerun. In the case 
of a positive or inconclusive test, the confirmatory West-
ern blot (W.b 2.4) serum test was run; this test is also used 
in the diáerentiation between HTLV-I and II viruses. The 
tests were performed by using kits Genelabs Diagnostics 
(Singapore - Malaysia).
HTLV-II prevalence was identified, and the epidemio-
logical data of positive cases was tabulated for statistical 
analysis by using the soá ware SPSS.
The study was evaluated and approved by the Research 
Ethics Committee of the Universidade Federal do Ceará 
under the Protocol COMEPE no. 39/10, March 25, 2010.
RESULTS
From 2001 to 2008, 679,610 donor blood samples were 
serologically assessed for HTLV-I/II at the Blood Center 
Net of Ceará; the samples were collected at the blood do-
nation (first sample), with 351 (0.05%) testing positive or 
inconclusive by the ELISA test and thus, the subjects were 
invited to come to the Blood Center for a new sample col-
lection (second sample), with the ELISA test being rerun. 
Among donators invited for a second sample collection, 
289 (82.3%) attended and 62 (17.7%) did not.
By analyzing the second sample, 229 of the 289 
(72.2%) tested positive or inconclusive and were re-
ferred for a Western blot confirmatory test, with the fol-
lowing results being achieved: 27 (11.8%) negative re-
sults, 38 (16.6%) undetermined results, and 164 (71.6%) 
positive results. A readingáofá“bands” in theá164áposi-
tive samplesá showed:á HTLV-I-114á (69.5%),á HTLV-
IIá 33á (20.1%),á HTLVá Iá andá IIá 7á (4.3%)á (dualinfec-
tion)áandáuntypedá10á(6.1%). Thus, HTLV-II prevalence in 
the total of donors was 0.006%.
The donors with a positive test only for HTLV-II com-
prised: 18 (54.5%) males and 15 females (45,5%). Regard-
ing the race, 2 (6.1%) were Caucasian, 26 (78.8%) were 
mixed and 5 were Afro-descendent. Twenty-four (72.7%) 
were from Fortaleza, while 9 (27.3%) were from other 
towns in the state of Ceará. Regarding the marital status, 
the distribution was as follows: 17 (51.5%) married/con-
sensual union, 12 (36.4%) were single, and other status 
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Table 1 – Characteristics of blood donors at the Blood Center Net of Ceará, with positive results for HTLV type II and HTLV 
type I following the confirmatory test by Western Blot
Characteristics
Type II Type I and II Total
n % n % n %
Gender
Male 18 54.5 05 71.4 23 57.5
Female 15 45.5 02 28.6 07 42.5
Racial group
Caucasian 02 6.1 01 14.3 03 7.5
Mixed 26 78.8 05 71.4 31 77.5
Afro-descendent 05 15.2 01 14.3 06 15.0
Marital status
Single 12 36.4 03 42.9 15 37.5
Married/consensual union  17 51.5 03 42.9 20 50.0
Others 04 12.1 01 14.2 05 12.5
Education
Incomplete elementary school  10 30.3 03 42.9 13 32.5
Complete elementary school 07 21.2 03 42.9 10 25.0
Incomplete high school 01 3.0 00 00 01 2.5
Complete high school 11 33.3 01 14.3 12 30.0
Incomplete higher education 02 6.1 00 00 02 5.0
Higher education 00 0.0 00 00 00 00
No Information 02 6.1 00 00 02 5.0
had 4 (12.1%) reports. Eleven donors (33.3%) reported a 
complete high school education, 7 (21.2%) had complete 
elementary school education, 1 (3%) had incomplete high 
school education, 2 (6.1%) incomplete higher education 
and no donors had a complete university education. The 
age of the group with HTLV-II ranged from 19 to 56 years, 
with a mean age of higher 8.2 (SD=11.2) (Table1). The 
seven patients with HTLV-I and II were five males and two 
females, five of a mixed race, four from Fortaleza, three 
married people, one with a complete high school educa-
tion and none with a higher education either complete or 
incomplete (Table1). The age of the group having HTLV-I 
and II ranged from 22 to 54 years, with a mean of 37.2 
(DP=12.2) years. HTLV-II prevalence for males was 
0.0033% and 0.0041% for females.
DISCUSSION
HTLV-II is endemic in native groups in Americas and 
in intravenous drug users in North and South Americas, 
Europe and Southeast of Asia12. It is considered a New 
World virus coming from Asia to Americas via migration 
of infected populations through the Bering Strait between 
10,000 and 40,000 years ago16.
In Brazil, the virus was investigated in 26 native com-
munities living in six Northern and Northeastern States 
(Amapá, Roraima, Amazonas, Rondônia, Pará e Maran-
hão) with seroepidemiological and retrospective studies 
in 1,382 serum samples tested by an immunoenzymatic 
assay, and positive cases underwent the Western Blot 2.4 
(Genelabs Diagnostics [Singapore, Malaysia]) test to con-
firm and diáerentiate between the viruses I and II. In three 
of these tribes, five positive samples for HTLV-I were iden-
tified and, in 17, positive cases for HTLV-II were found, 
showing Brazilian Amazonia represents an endemic area 
of HTLV-II17. In 1996, in a study conducted in blood do-
nors in the State of Pará, HTLV-II was detected in an ur-
ban area, with higher virus prevalence in females18.
In Ceará, samples of 250,326 blood donors were ana-
lyzed at HEMOCE from 1997 to 2000 by using screening 
tests through ELISA and confirmatory tests with Western 
Blot, with 261 (0.10%) positive samples being found, 182 
(69.7%) type I, 59 (22.6%) type II and 9 (3.4%) were coin-
fected (I and II). HTLV-II prevalence in the total of donors 
was 0.27%. Considering only the screening test by the ELI-
SA method in 340,059 donors from 1995 to 2000, 0.67% 
of reactive samples were found19. In the current sample, 
which was enlarged in time and number, a significantly 
lower value was found (pá<á0.001). In four Bahia towns20, 
HTLV-II was not found, the same occurring in Monterrey, 
Mexico21 and in Arequipa, Peru22. The knowledge of the 
seroprevalence, mainly for HTLV-II, among young wom-
en allows a better planning in public health programs, 
considering breastfeeding by infected mothers has a high 
mother-infant transmission rate4,23-26.
HTLV-II has a diáerent pathogenesis from HTLV-I; 
however, it has been associated with myelopathic condi-
tions27,28, requiring a special attention upon looking for 
HTLV-II-specific clinical manifestations17. However, there 
are coinfection cases, as in the current study, where 4.3% 
of infected patients had both virus types.
FRANCISCA VÂNIA BARRETO AGUIAR FERREIRA GOMES ET AL.
312 Rev Assoc Med Bras 2011; 57(3):309-312
This study has the database retrospective survey as a 
limitation, which, even with a well-defined protocol ap-
propriately filled most of the time, led to a number of in-
vestigation losses. Recent result report29 of a prospective 
multicenter study evaluates the impact of the retroviral in-
fection on survival and death cause in blood donors diag-
nosed with HTLV at the donation and followed for a mean 
time of 15.9 years. A significant HTLV-II association with 
all death causes and mortality from cancer was observed, 
suggesting biological eects of HTLV-II coinfection with 
other carcinogenic viruses, socioeconomic criteria or oth-
er factors inuence the neoplasm arising.
CONCLUSION
The current study data shows the presence of HTLV-II is 
universal in the State of Ceará and that there is a coinfec-
tion occurrence (I + II). The prevalence is 0.006% and the 
distribution is similar among males and females, with most 
of them coming from an urban center and having a high 
school education. Despite the low prevalence, the public 
health policy involving blood transfusion must be stimu-
lated as a multidisciplinary eáort by identifying the cases 
and preventing the virus spread, specifically among women 
due to the risk of transmission through breastfeeding.
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